The 3rd International Conference on Biomedical Engineering and Biotechnology (iCBEB2014)
The Exhibition on Biotechnology and Equipment
The Exhibition on Biotechnology and Equipment
September 25-28, 2014, Beijing, China
Director of the Centre for Evidence-Based Pharmacotherapy, Nottingham, UK.
Speech:
Genomics and the transformation of the clinical, chemical and pharmaceutical sciences.
Recent publications
1. Newton R, Lithgow J, Li Wan Po A, Bennett C. How Will Pharmacogenetics Impact on Pharmacy Practice? Pharmacists' Views and Educational Priorities. Birmingham, UK: National Genetics Education and Development Centre; 2007.
2. Li-Wan-Po A. The human genome: its modifications and interactions with those of the microbiome, and the practice of genomic medicine. Discov Med 2013;15(84):283-90.
3. Li-Wan-Po A, Chen S, Petersen B, Wang Y. No need for rescue medication (NNR) as an easily interpretable efficacy outcome measure in analgesic trials: validation in an individual-patient meta-analysis of dental pain placebo-controlled trials of naproxen. J Clin Pharm Ther 2013;38(1):36-40.
4. Li-Wan-Po A. Pertuzumab plus trastuzumab in metastatic breast cancer. N Engl J Med 2012;366(14):1348-9; author reply 9-50.
5. Li-Wan-Po A, Loeys B, Farndon P, Latham D, Bradley C. Preventing the aortic complications of Marfan syndrome: a case-example of translational genomic medicine. Br J Clin Pharmacol 2011;72:6-17.
6. Li-Wan-Po A, Farndon PA, Kobayashi S, Mitsudomi T, Potter VA. The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example. Ann Pharmacother 2011:263-75.
7. Li-Wan-Po A, Farndon P. Barking up the wrong genome--we are not alone. J Clin Pharm Ther 2011;36(2):125-7.
8. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol 2010;69(3):222-30.
9. Li-Wan-Po A, Farndon P, Craddock C, Griffiths M. Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example. Eur J Clin Pharmacol 2010;66(4):369-74.
10. Li-Wan-Po A, Farndon P, Cooley C, Lithgow J. When Is a Genetic Test Suitable for Prime Time? Predicting the Risk of Prostate Cancer as a Case-Example. Public Health Genomics 2009;13:55-62.
11. Li-Wan-Po A. How genomic scans can help predict altered drug response or disease. Pharmaceutical Journal 2009;283:537-8.
12. Li-Wan-Po A. Postmarketing surveillance. In: Kennewell PD, ed. Global perspective. Amsterdam: Elsevier; 2007:755-78.
13. Li-Wan-Po A. Personalised medicine: who is an Asian? Lancet 2007;369(9575):1770-1.
14. Li Wan Po A. Dose-response of minor analgesics in acute pain. Br J Clin Pharmacol 2007;63(3):268-70.
15. Li Wan Po A, Girard T. Succinylcholine: still beautiful and mysterious after all these years. J Clin Pharm Ther 2005;30(6):497-501.
